Adjusted earnings per share was $0.91 for the quarter, up 12% compared to the same quarter last year.
We expect these investments and the impact of cycling COVID-19 vaccine revenue will be fully offset by tailwinds in our model and allow us to grow adjusted net earnings per diluted share to between $3.75 and $3.85.
